Phenomenology, Structure, and Dynamic of Psychedelic States

Preller, K. H., & Vollenweider, F. X. | Current Topics in Behavioral Neurosciences | 27 December 2016

Predicting the Abuse Liability of Entactogen-Class, New and Emerging Psychoactive Substances via Preclinical Models of Drug Self-administration

Aarde, S. M., & Taffe, M. A. | Current Topics in Behavorial Neuroscience | 2 December 2016

Effects of dextromethorphan on MDMA-induced serotonergic aberration in the brains of non-human primates using [123I]-ADAM/SPECT

Ma, K. H., Liu, T. T., Weng, S. J., Chen, C. F. F., Huang, Y. S., Chueh, S. H., ... & Huang, W. S. | Scientific Reports | 1 December 2016

The serotonin 5-HT2C receptor and the non-addictive nature of classic hallucinogens

Canal, C. E., & Murnane, K. S. | Journal of Psychopharmacology | 15 November 2016

MOLECULAR DOCKING STUDIES ON THE THERAPEUTIC TARGETS OF ALZHEIMER DISEASE (ACHE AND BCHE) USING NATURAL BIOACTIVE ALKALOIDS

Jyothi, P., & Yellamma, K. | International Journal of Pharmacy and Pharmaceutical Sciences | 1 November 2016

Of Roots and Fruits A Comparison of Psychedelic and Nonpsychedelic Mystical Experiences

Yaden, D. B., Le Nguyen, K. D., Kern, M. L., Belser, A. B., Eichstaedt, J. C., Iwry, J., ... & Newberg, A. B. | Journal of Humanistic Psychology | 24 October 2016

Creativity and Psychoactive Substance Use: A Systematic Review

Iszáj, F., Griffiths, M. D., & Demetrovics, Z. | International Journal of Mental Health and Addiction | 20 October 2016

Lysergic Acid Diethylamide and mystical experiences

Lyvers, M. | The neuropathology of drug addictions and substance misuse | 1 October 2016

The Psychedelic Policy Quagmire: Health, Law, Freedom, and Society

Van Hagen, A. G. | BJPsych Bull | 11 August 2016

Clinical Applications of Hallucinogens: A Review

Garcia-Romeu, A., Kersgaard, B., & Addy, P. H. | Experimental and clinical psychopharmacology | 1 July 2016

Abuse potential of methylenedioxymethamphetamine (MDMA) and its derivatives in zebrafish: role of serotonin 5HT2-type receptors

Ponzoni, L., Daniela, B., & Sala, M. | Psychopharmacology | 16 June 2016

Return of the lysergamides. Part II: Analytical and behavioural characterization of N6-allyl-6-norlysergic acid diethylamide (AL-LAD) and (2’S,4’S)-lysergic acid 2,4-dimethylazetidide (LSZ)

Brandt, S. D., Kavanagh, P. V., Westphal, F., Elliott, S. P., Wallach, J., Colestock, T., ... & Halberstadt, A. L. | Drug testing and analysis | 6 June 2016

Human Pharmacology of Mephedrone in Comparison to MDMA

Papaseit, E., Pérez-Mañá, C., Mateus, J. A., Pujadas, M., Fonseca, F., Torrens, M., ... & Farré, M. | Neuropsychopharmacology | 20 May 2016

Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens

Rickly, A., Moning, O., Hoener, M., Liechti, M. | European Neuropsychopharmacology | 20 May 2016

Ego-Dissolution and Psychedelics: Validation of the Ego-Dissolution Inventory (EDI)

Nour, M. M., Evans, L., Nutt, D., & Carhart-Harris, R. L. | Frontiers in Human Neuroscience | 20 May 2016

Detailed pharmacological evaluation of methoxetamine (MXE), a novel psychoactive ketamine analogue—Behavioural, pharmacokinetic and metabolic studies in the Wistar rat

Horsley, R. R., Lhotkova, E., Hajkova, K., Jurasek, B., Kuchar, M., & Palenicek, T. | Brain Research Bulletin | 4 May 2016

Hallucinogen use and intimate partner violence: Prospective evidence consistent with protective effects among men with histories of problematic substance use

Walsh, Z., Hendricks, P. S., Smith, S., Kosson, D. S., Thiessen, M. S., Lucas, P., & Swogger, M. T. | Journal of psychopharmacology (Oxford, England) | 19 April 2016

Harmine stimulates neurogenesis of human neural cells in vitro

Dakic, V., de Moraes Maciel, R., Drummond, H., Nascimento, J. M., Trindade, P., & Rehen, S. K. | PeerJ Preprints | 14 April 2016

How psychoactive drugs shape human culture: a multi-disciplinary perspective

Wadley, G. | Brain Research Bulletin | 12 April 2016

A systematic review of the effects of novel psychoactive substances ‘legal highs’ on people with severe mental illness

Gray, R., Bressington, D., Hughes, E., & Ivanecka, A. | Journal of Psychiatric and Mental Health Nursing | 1 April 2016

Modification of 5-methoxy-N,N-dimethyltryptamine-induced hyperactivity by monoamine oxidase A inhibitor harmaline in mice and the underlying serotonergic mechanisms

Jiang, X. L., Shen, H. W., & Yu, A. M. | Pharmacological Reports | 5 Februari 2016

Modulatory effect of the 5-HT1A agonist buspirone and the mixed non-hallucinogenic 5-HT1A/2A agonist ergotamine on psilocybin-induced psychedelic experience

Pokorny, T., Preller, K. H., Kraehenmann, R., & Vollenweider, F. X. | European Neuropsychopharmacology | 22 January 2016

Behavioral and pharmacokinetic interactions between monoamine oxidase inhibitors and the hallucinogen 5-methoxy-NN-dimethyltryptamine

Halberstadt, A. L. | Pharmacology Biochemistry and Behavior | 15 January 2016

Psychedelic Medicine: Is it a False Dawn or a Renaissance?

Ali, A. Y. | International Journal of Emergency Mental Health and Human Resilience | 1 January 2016

Cytochrome P450 inhibition potential of new psychoactive substances of the tryptamine class

Dinger, J., Woods, C., Brandt, S. D., Meyer, M. R., & Maurer, H. H. | Toxicology Letters | 17 November 2015